Compare Hut 8 Corp (HUT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs ResMed Inc. — how do they compare? Hut 8 Corp trades at $93.22 (market cap $10.94B), while ResMed Inc. trades at $225.91 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 3× Hut 8 Corp's market cap, and ResMed Inc. pays a 1.17% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| HUT | RMD | |
|---|---|---|
Market Cap | $10.94B | $32.61B |
Sector | Technology | Health |
52-Week High | $133.02 | $293.73 |
52-Week Low | $21.37 | $182.82 |
Enterprise Value | $18.38B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $91.66, up 7.0% today amid a broader neocloud rally following NVIDIA's $500 billion AI pledge. The stock shows a bearish technical trend with support at $87 and resistance at $92. Fundamentally, Q2 2026 revenue grew 81% year-over-year to $74 million, but net losses widened to -$226 million in 2025. The company is transitioning to an AI data center platform, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (94%) targets $165.11, citing AI infrastructure potential, but high execution risks and persistent losses pose threats. Near-term volatility is likely as the market weighs Beacon Point commercialization progress against earnings misses and negative cash flow from operations.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
